Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Targeted deletion of Vegfa in adult mice induces vision loss.

Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M.

J Clin Invest. 2012 Nov;122(11):4213-7. doi: 10.1172/JCI65157. Epub 2012 Oct 24.

2.

Anti-vascular endothelial growth factor treatment for retinal vein occlusions.

Campochiaro PA.

Ophthalmologica. 2012;227 Suppl 1:30-5. doi: 10.1159/000337157. Epub 2012 Apr 24. Review.

PMID:
22517123
3.

Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.

Pece A, Isola V, Piermarocchi S, Calori G.

Br J Ophthalmol. 2011 Jan;95(1):56-68. doi: 10.1136/bjo.2009.174060. Epub 2010 Jul 3.

PMID:
20601660
4.

Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors.

Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA.

PLoS One. 2008;3(11):e3554. doi: 10.1371/journal.pone.0003554. Epub 2008 Nov 3.

5.

Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.

Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM; American Academy of Ophthalmology.

Ophthalmology. 2008 Oct;115(10):1837-46. doi: 10.1016/j.ophtha.2008.08.012.

PMID:
18929163
6.

VEGF inhibition and renal thrombotic microangiopathy.

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE.

N Engl J Med. 2008 Mar 13;358(11):1129-36. doi: 10.1056/NEJMoa0707330.

7.

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.

Frangié C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D.

Lancet Oncol. 2007 Feb;8(2):177-8. No abstract available.

PMID:
17267332
8.

Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis.

Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M.

Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):967-72. Epub 2007 Jan 8.

9.

Ranibizumab for neovascular age-related macular degeneration.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group.

N Engl J Med. 2006 Oct 5;355(14):1419-31.

10.

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.

Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM.

Ophthalmology. 2006 Oct;113(10):1706-12.

PMID:
17011952
11.

Circulating angiogenic factors and the risk of preeclampsia.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA.

N Engl J Med. 2004 Feb 12;350(7):672-83. Epub 2004 Feb 5.

12.

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE.

J Clin Invest. 2003 Mar;111(5):707-16.

13.

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA.

J Clin Invest. 2003 Mar;111(5):649-58.

14.

VEGF is required for growth and survival in neonatal mice.

Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N.

Development. 1999 Mar;126(6):1149-59.

15.

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.

Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A.

Nature. 1996 Apr 4;380(6573):435-9.

PMID:
8602241
16.

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE.

Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10457-61.

Items per page

Supplemental Content

Write to the Help Desk